Cullinan Therapeutics, Inc. (CGEM): Shareholders' Equity
$408.73M
As of 2025-12-31
$321.75M
As of 2026-06-30
-8.6%
3-year compound annual growth
+15.5%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $408.73M | -30.8% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $590.33M | +30.1% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $453.70M | -15.2% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $535.03M | +25.9% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $424.97M | +113.5% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $199.01M | n/a | 2022-03-17, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $408.73M | -30.8% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $233.06M | +4.5% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $102.73M | -60.4% |
| Vor Biopharma Inc. (VOR) | 2025-12-31 | -$164.31M | n/m |
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $160.88M | -35.8% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $292.54M | -30.7% |
| Vericel Corp (VCEL) | 2025-12-31 | $354.64M | +21.5% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $245.49M | -33.4% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | -$500.47M | n/m |
Compare CGEM, GLUE, RGNX, VOR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗